Broad Institute Joins CRISPR Patent Pool Talks – Genetic Engineering & Biotechnology News (blog)
|
Broad Institute Joins CRISPR Patent Pool Talks
Genetic Engineering & Biotechnology News (blog) The Broad Institute of MIT and Harvard said today it has joined discussions to create a non-exclusive CRISPR-Cas9 joint licensing pool being coordinated by MPEG LA, which operates patent pool licensing programs across institutions and countries. |
Reuters |
FDA panel to focus on safety of Novartis gene therapy drug
Reuters (Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug when it meets to review the product on Wednesday. The keenly anticipated preliminary review of the … FDA Advisory Board and Novartis to Discuss Leukemia Gene Therapy WednesdayRare Disease Report What to watch for as Novartis heads to the FDA with a novel cancer therapySTAT |
|
Monoclonal Antibodies as Immunotherapy “Magic Bullets”
Cancer Therapy Advisor If we were to imagine the perfect target for immunotherapy, it would be a molecular structure present only on the cancer. A structure of this kind has, however, proved elusive. The identification of cancer antigens that are specific or sometimes unique … |
|
BRIEF-Crispr Therapeutics, Neon Therapeutics enter research collaboration
Reuters Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news … |
Reuters |
FDA panel to focus on safety of Novartis gene therapy drug
Reuters The drugs use a new technology known as CAR-T, or chimeric antigen receptor T–cell therapy, which harnesses the body’s own immune cells to recognize and attack malignant cells. If approved they are expected to cost up to $500,000 and generate billions … |
Reuters |
FDA panel to focus on safety of Novartis gene therapy drug
Reuters (Reuters) – The U.S. Food and Drug Administration will ask a panel of advisors to focus on the safety of Novartis AG’s experimental gene therapy drug when it meets to review the product on Wednesday. The keenly anticipated preliminary review of the … FDA Advisory Board and Novartis to Discuss Leukemia Gene Therapy WednesdayRare Disease Report Before Key Meeting, FDA Stresses Risks of Novartis CAR-T Cancer TherapyXconomy |